Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3525 in Relapsed/Refractory PTCL
NCT04615468Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQ-B3525 in peripheral T-cell lymphoma (PTCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
TQ-B3525
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04615468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615468.